Premium
Spironolactone and canrenoate‐K: Relative potency at steady state
Author(s) -
Ramsay Lawrence,
Asbury Michael,
Shelton John,
Harrison Ian
Publication year - 1977
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1977215602
Subject(s) - spironolactone , metabolite , endocrinology , medicine , potency , urine , chemistry , mineralocorticoid , aldosterone , pharmacology , biochemistry , in vitro
Relative dose ratios of the mineralocorticoid antagonists spironolactone (100 mg and 200 mg daily) and canrenoate‐K (200 mg daily) at steady state were defined in six healthy subjects with fiudrocortisone as the mineralocorticoid agonist. The urine log 10 Na/K responses during spironolactone treatments were consistent with the law of mass action. The potency of canrenoate‐K was 0.68 (95% C.L. 0.53 to 0.89) that of spironolactone on a weight basis. Approximately 72% of the renal antimineralocorticoid activity of spironolactone could be attributed to the metabolite canrenone. The results at steady state are contrasted with those of a previous study comparing single doses of spironolactone and canrenoate‐K.